Pharmacological inhibition of the Wnt pathway by porcupine inhibition also showed increased susceptibility to temozolomide (TMZ, the first-line chemotherapeutic agent that has been used to treat gliomas for more than a decade) treatment, presumably involving downregulation of aldehyde dehydrogenase 3 family member A1 (ALDH3A1) [12]. The gene discussed is ALDH3A1; the disease is glioma.